Mitchell Sinkler & Starr’s GSK GSK Stock Holding History

Mitchell Sinkler & Starr’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4,658	Closed	-$207K	–	89
2017 Q4	$207K	Sell	4,658 -1,200	-20%	-$55.4K	0.31%	79
2017 Q3	$297K	Buy	5,858 +800	+16%	+$40.6K	0.47%	67
2017 Q2	$273K	Buy	5,058 +80	+2%	+$4.26K	0.45%	68
2017 Q1	$262K	Sell	4,978 -3,520	-41%	-$179K	0.43%	70
2016 Q4	$409K	Sell	8,498 -728	-8%	-$36K	0.57%	58
2016 Q3	$497K	Hold	9,226	–	–	0.78%	43
2016 Q2	$500K	Sell	9,226 -720	-7%	-$37.9K	0.68%	48
2016 Q1	$504K	Hold	9,946	–	–	0.7%	48
2015 Q4	$502K	Sell	9,946 -2,400	-19%	-$122K	0.69%	48
2015 Q3	$593K	Hold	12,346	–	–	0.76%	42
2015 Q2	$643K	Buy	12,346 +188	+2%	+$10.6K	0.76%	43
2015 Q1	$701K	Hold	12,158	–	–	0.79%	43
2014 Q4	$650K	Hold	12,158	–	–	0.73%	47
2014 Q3	$699K	Sell	12,158 -400	-3%	-$24.5K	0.78%	43
2014 Q2	$840K	Hold	12,558	–	–	0.9%	38
2014 Q1	$839K	Hold	12,558	–	–	0.94%	38
2013 Q4	$838K	Sell	12,558 -2,366	-16%	-$153K	0.94%	39
2013 Q3	$936K	Sell	14,924 -4,012	-21%	-$258K	1.07%	37
2013 Q2	$1.18M	Buy	+18,936	New	+$1.2M	0.26%	74

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Mitchell Sinkler & Starr's GSK Position: Q1 2018 in Review

Mitchell Sinkler & Starr sold out of GSK (GSK) in Q1 2018, closing a stake of 4,658 shares — an estimated $207K sold.

Mitchell Sinkler & Starr first reported a position in GSK in Q2 2013 and held it in 19 quarters. The position peaked at $1.18M in Q2 2013. 778 funds tracked by Wall St. Rank hold GSK as of Q1 2018.

Mitchell Sinkler & Starr reported no remaining GSK position as of Q1 2018 after selling out during the quarter.
Mitchell Sinkler & Starr sold 4,658 GSK shares in Q1 2018, an estimated $207K.
Mitchell Sinkler & Starr first reported a position in GSK in Q2 2013 and held it in 19 quarters.
Mitchell Sinkler & Starr's GSK position peaked at $1.18M in Q2 2013.
778 funds tracked by Wall St. Rank held GSK as of Q1 2018.

Based on Mitchell Sinkler & Starr's 13F filing for Q1 2018, filed 13 Apr 2018.